Ignite Creation Date:
2025-12-25 @ 2:16 AM
Ignite Modification Date:
2026-04-14 @ 12:33 PM
Study NCT ID:
NCT02116660
Status:
TERMINATED
Last Update Posted:
2019-04-08
First Post:
2014-04-15
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-09-03
Start Date Type:
ACTUAL
Primary Completion Date:
2017-07-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-07-10
Completion Date Type:
ACTUAL
First Submit Date:
2014-04-15
First Submit QC Date:
None
Study First Post Date:
2014-04-17
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-06-12
Results First Submit QC Date:
None
Results First Post Date:
2019-04-08
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-04-05
Last Update Post Date:
2019-04-08
Last Update Post Date Type:
ACTUAL